Literature DB >> 15963030

The GTPase RhoA increases utrophin expression and stability, as well as its localization at the plasma membrane.

Armelle Bonet-Kerrache1, Mathieu Fortier, Franck Comunale, Cécile Gauthier-Rouvière.   

Abstract

The Rho family of small GTPases are signalling molecules involved in cytoskeleton remodelling and gene transcription. Their activities are important for many cellular processes, including myogenesis. In particular, RhoA positively regulates skeletal-muscle differentiation. We report in the present study that the active form of RhoA increases the expression of utrophin, the autosomal homologue of dystrophin in the mouse C2C12 and rat L8 myoblastic cell lines. Even though this RhoA-dependent utrophin increase is higher in proliferating myoblasts, it is maintained during myogenic differentiation. This occurs via two mechanisms: (i) transcriptional activation of the utrophin promoter A and (ii) post-translational stabilization of utrophin. In addition, RhoA increases plasma-membrane localization of utrophin. Thus RhoA activation up-regulates utrophin levels and enhances its localization at the plasma membrane.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15963030      PMCID: PMC1276923          DOI: 10.1042/BJ20050024

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  45 in total

Review 1.  Rho GTPases and cadherin-based cell adhesion in skeletal muscle development.

Authors:  Sophie Charrasse; Marie Causeret; Franck Comunale; Armelle Bonet-Kerrache; Cécile Gauthier-Rouvière
Journal:  J Muscle Res Cell Motil       Date:  2003       Impact factor: 2.698

2.  The adaptor protein 3BP2 associates with VAV guanine nucleotide exchange factors to regulate NFAT activation by the B-cell antigen receptor.

Authors:  Isabelle Foucault; Séverine Le Bras; Céline Charvet; Chéol Moon; Amnon Altman; Marcel Deckert
Journal:  Blood       Date:  2004-09-02       Impact factor: 22.113

3.  Control of expression of the lectin-like protein Reg-1 by gastrin: role of the Rho family GTPase RhoA and a C-rich promoter element.

Authors:  Felicity J Ashcroft; Andrea Varro; Rod Dimaline; Graham J Dockray
Journal:  Biochem J       Date:  2004-07-15       Impact factor: 3.857

Review 4.  Duchenne muscular dystrophy and dystrophin: pathogenesis and opportunities for treatment.

Authors:  Kristen J Nowak; Kay E Davies
Journal:  EMBO Rep       Date:  2004-09       Impact factor: 8.807

5.  Prevention of pathology in mdx mice by expression of utrophin: analysis using an inducible transgenic expression system.

Authors:  S Squire; J M Raymackers; C Vandebrouck; A Potter; J Tinsley; R Fisher; J M Gillis; K E Davies
Journal:  Hum Mol Genet       Date:  2002-12-15       Impact factor: 6.150

Review 6.  Novel therapies for Duchenne muscular dystrophy.

Authors:  Robert Kapsa; Andrew J Kornberg; Edward Byrne
Journal:  Lancet Neurol       Date:  2003-05       Impact factor: 44.182

7.  A-utrophin up-regulation in mdx skeletal muscle is independent of regeneration.

Authors:  Andrew P Weir; Jennifer E Morgan; Kay E Davies
Journal:  Neuromuscul Disord       Date:  2004-01       Impact factor: 4.296

8.  Okadaic acid augments utrophin in myogenic cells.

Authors:  Marianna Rodova; Kyle Brownback; Michael J Werle
Journal:  Neurosci Lett       Date:  2004-06-10       Impact factor: 3.046

9.  Marked reduction of focal adhesion kinase, serum response factor and myocyte enhancer factor 2C, but increase in RhoA and myostatin in the hindlimb dy mouse muscles.

Authors:  Kunihiro Sakuma; Ryuta Nakao; Shuichiro Inashima; Miyuki Hirata; Toshikazu Kubo; Masahiro Yasuhara
Journal:  Acta Neuropathol       Date:  2004-06-24       Impact factor: 17.088

Review 10.  The new frontier in muscular dystrophy research: booster genes.

Authors:  Eva Engvall; Ulla M Wewer
Journal:  FASEB J       Date:  2003-09       Impact factor: 5.191

View more
  8 in total

1.  All-trans-retinoic acid promotes trafficking of human concentrative nucleoside transporter-3 (hCNT3) to the plasma membrane by a TGF-beta1-mediated mechanism.

Authors:  Paula Fernández-Calotti; Marçal Pastor-Anglada
Journal:  J Biol Chem       Date:  2010-02-19       Impact factor: 5.157

Review 2.  Viral-mediated gene therapy for the muscular dystrophies: successes, limitations and recent advances.

Authors:  Guy L Odom; Paul Gregorevic; Jeffrey S Chamberlain
Journal:  Biochim Biophys Acta       Date:  2006-09-26

3.  Pathological pattern of Mdx mice diaphragm correlates with gradual expression of the short utrophin isoform Up71.

Authors:  Karim Hnia; Sylvie Tuffery-Giraud; Marianne Vermaelen; Gerald Hugon; Delphine Chazalette; Ahmed Masmoudi; François Rivier; Dominique Mornet
Journal:  Biochim Biophys Acta       Date:  2006-03

Review 4.  Targeting IRES-dependent translation as a novel approach for treating Duchenne muscular dystrophy.

Authors:  Christine Péladeau; Bernard J Jasmin
Journal:  RNA Biol       Date:  2020-11-19       Impact factor: 4.652

5.  Translational regulation of utrophin by miRNAs.

Authors:  Utpal Basu; Olga Lozynska; Catherine Moorwood; Gopal Patel; Steve D Wilton; Tejvir S Khurana
Journal:  PLoS One       Date:  2011-12-27       Impact factor: 3.240

6.  IRES-mediated translation of utrophin A is enhanced by glucocorticoid treatment in skeletal muscle cells.

Authors:  Pedro Miura; Meghan Andrews; Martin Holcik; Bernard J Jasmin
Journal:  PLoS One       Date:  2008-06-11       Impact factor: 3.240

7.  Tadalafil Treatment Delays the Onset of Cardiomyopathy in Dystrophin-Deficient Hearts.

Authors:  David W Hammers; Margaret M Sleeper; Sean C Forbes; Ai Shima; Glenn A Walter; H Lee Sweeney
Journal:  J Am Heart Assoc       Date:  2016-08-09       Impact factor: 5.501

8.  Identification of therapeutics that target eEF1A2 and upregulate utrophin A translation in dystrophic muscles.

Authors:  Christine Péladeau; Nadine Adam; Lucas M Bronicki; Adèle Coriati; Mohamed Thabet; Hasanen Al-Rewashdy; Jason Vanstone; Alan Mears; Jean-Marc Renaud; Martin Holcik; Bernard J Jasmin
Journal:  Nat Commun       Date:  2020-04-24       Impact factor: 14.919

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.